Jan Öhrström
Vorsitzender bei ONWARD MEDICAL N.V.
Aktive Beziehungen
| Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
|---|---|---|---|---|
| Grégoire Courtine | M | 49 |
Onward Medical SA
 Onward Medical SA BiotechnologyHealth Technology ONWARD Inc develops medical devices. It also provides stimulation system to rehabilitate individuals with spinal cord injury. The company was founded by Jocelyn Bloch, Sjaak Deckers, Grégoire Courtine, and Vincent Delattre in December 2014 and is headquartered in Lausanne, Switzerland. | 10 Jahre |
| Vincent Delattre | M | - |
Onward Medical SA
Onward Medical SA BiotechnologyHealth Technology ONWARD Inc develops medical devices. It also provides stimulation system to rehabilitate individuals with spinal cord injury. The company was founded by Jocelyn Bloch, Sjaak Deckers, Grégoire Courtine, and Vincent Delattre in December 2014 and is headquartered in Lausanne, Switzerland. | 10 Jahre |
| Heather Franklin | F | 58 |
Blaze Bioscience, Inc.
 Blaze Bioscience, Inc. Medical/Nursing ServicesHealth Services Blaze Bioscience, Inc. develops tumor paint products and Optide-based guided therapeutics for cancer patients. The firm provides BLZ-100. The company was founded by James M. Olson in 2010 and is headquartered in Seattle, WA.
ZymoGenetics, Inc.
 ZymoGenetics, Inc. Pharmaceuticals: MajorHealth Technology ZymoGenetics, Inc. develops protein based drugs. It focuses on the discovery, development, manufacture, and commercialization of therapeutic proteins for the treatment of human diseases, including homeostasis, inflammatory and autoimmune diseases, cancer, and viral infections. The company was founded by Earl W. Davie, Benjamin D. Hall and Michael Smith in 1981 and is headquartered in Seattle, WA. | 23 Jahre |
| Lars Fruergaard Jorgensen | M | 58 | 33 Jahre | |
| Tom Maguire | M | - | 8 Jahre | |
| Fredericus Colen | M | 71 |
Onward Medical SA
Onward Medical SA BiotechnologyHealth Technology ONWARD Inc develops medical devices. It also provides stimulation system to rehabilitate individuals with spinal cord injury. The company was founded by Jocelyn Bloch, Sjaak Deckers, Grégoire Courtine, and Vincent Delattre in December 2014 and is headquartered in Lausanne, Switzerland. | 7 Jahre |
| John Paul de Koning | M | 55 |
Varmx BV
 Varmx BV BiotechnologyHealth Technology VarmX BV is a spin-off from Leiden University Medical Center (LUMC) founded in 2016 by Professor Pieter Reitsma, a world-leading expert in hemostasis and thrombosis. VarmX is based in Leiden, NL. The Dutch company's lead compound, VMX-C001, is a modified recombinant blood factor X developed for the treatment of severe spontaneous bleeding and for the prevention of bleeding during urgent surgery in patients taking oral factor Xa inhibitors (FXa DOACs) as anticoagulation therapy. The company is supported by a strong syndicate of investors. Jan K. Öhrström has been the CEO of the company since 2018.
Onward Medical SA
Onward Medical SA BiotechnologyHealth Technology ONWARD Inc develops medical devices. It also provides stimulation system to rehabilitate individuals with spinal cord injury. The company was founded by Jocelyn Bloch, Sjaak Deckers, Grégoire Courtine, and Vincent Delattre in December 2014 and is headquartered in Lausanne, Switzerland. | 8 Jahre |
| Ian Curtis | M | 56 |
Onward Medical SA
Onward Medical SA BiotechnologyHealth Technology ONWARD Inc develops medical devices. It also provides stimulation system to rehabilitate individuals with spinal cord injury. The company was founded by Jocelyn Bloch, Sjaak Deckers, Grégoire Courtine, and Vincent Delattre in December 2014 and is headquartered in Lausanne, Switzerland. | 5 Jahre |
| Roel Bulthuis | M | - |
Varmx BV
Varmx BV BiotechnologyHealth Technology VarmX BV is a spin-off from Leiden University Medical Center (LUMC) founded in 2016 by Professor Pieter Reitsma, a world-leading expert in hemostasis and thrombosis. VarmX is based in Leiden, NL. The Dutch company's lead compound, VMX-C001, is a modified recombinant blood factor X developed for the treatment of severe spontaneous bleeding and for the prevention of bleeding during urgent surgery in patients taking oral factor Xa inhibitors (FXa DOACs) as anticoagulation therapy. The company is supported by a strong syndicate of investors. Jan K. Öhrström has been the CEO of the company since 2018.
Onward Medical SA
Onward Medical SA BiotechnologyHealth Technology ONWARD Inc develops medical devices. It also provides stimulation system to rehabilitate individuals with spinal cord injury. The company was founded by Jocelyn Bloch, Sjaak Deckers, Grégoire Courtine, and Vincent Delattre in December 2014 and is headquartered in Lausanne, Switzerland. | - |
| David Marver | M | - |
Onward Medical SA
Onward Medical SA BiotechnologyHealth Technology ONWARD Inc develops medical devices. It also provides stimulation system to rehabilitate individuals with spinal cord injury. The company was founded by Jocelyn Bloch, Sjaak Deckers, Grégoire Courtine, and Vincent Delattre in December 2014 and is headquartered in Lausanne, Switzerland. | 4 Jahre |
| Andy Dolan | M | - |
Onward Medical SA
Onward Medical SA BiotechnologyHealth Technology ONWARD Inc develops medical devices. It also provides stimulation system to rehabilitate individuals with spinal cord injury. The company was founded by Jocelyn Bloch, Sjaak Deckers, Grégoire Courtine, and Vincent Delattre in December 2014 and is headquartered in Lausanne, Switzerland. | 3 Jahre |
| Mila Lobanova | F | - |
Blaze Bioscience, Inc.
Blaze Bioscience, Inc. Medical/Nursing ServicesHealth Services Blaze Bioscience, Inc. develops tumor paint products and Optide-based guided therapeutics for cancer patients. The firm provides BLZ-100. The company was founded by James M. Olson in 2010 and is headquartered in Seattle, WA. | - |
| Karsten Munk Knudsen | M | 53 | 25 Jahre | |
| Henrik Ehlers Wulff | M | 54 | 25 Jahre | |
| James C. Towne | M | - |
Blaze Bioscience, Inc.
Blaze Bioscience, Inc. Medical/Nursing ServicesHealth Services Blaze Bioscience, Inc. develops tumor paint products and Optide-based guided therapeutics for cancer patients. The firm provides BLZ-100. The company was founded by James M. Olson in 2010 and is headquartered in Seattle, WA. | - |
| Per Stahl Skov | M | 78 |
University of Copenhagen
| 44 Jahre |
| Vivian Riefberg | F | 63 | 2 Jahre | |
| Regina Hodits | M | 53 |
Onward Medical SA
Onward Medical SA BiotechnologyHealth Technology ONWARD Inc develops medical devices. It also provides stimulation system to rehabilitate individuals with spinal cord injury. The company was founded by Jocelyn Bloch, Sjaak Deckers, Grégoire Courtine, and Vincent Delattre in December 2014 and is headquartered in Lausanne, Switzerland. | 8 Jahre |
| Dennis M. Miller | M | 61 |
Blaze Bioscience, Inc.
Blaze Bioscience, Inc. Medical/Nursing ServicesHealth Services Blaze Bioscience, Inc. develops tumor paint products and Optide-based guided therapeutics for cancer patients. The firm provides BLZ-100. The company was founded by James M. Olson in 2010 and is headquartered in Seattle, WA.
ZymoGenetics, Inc.
ZymoGenetics, Inc. Pharmaceuticals: MajorHealth Technology ZymoGenetics, Inc. develops protein based drugs. It focuses on the discovery, development, manufacture, and commercialization of therapeutic proteins for the treatment of human diseases, including homeostasis, inflammatory and autoimmune diseases, cancer, and viral infections. The company was founded by Earl W. Davie, Benjamin D. Hall and Michael Smith in 1981 and is headquartered in Seattle, WA. | - |
| Peter Jan Elvire Byloos | M | 56 | 6 Jahre | |
| John Murphy | M | 57 | 4 Jahre | |
| Guillem Laporta | M | - |
Varmx BV
Varmx BV BiotechnologyHealth Technology VarmX BV is a spin-off from Leiden University Medical Center (LUMC) founded in 2016 by Professor Pieter Reitsma, a world-leading expert in hemostasis and thrombosis. VarmX is based in Leiden, NL. The Dutch company's lead compound, VMX-C001, is a modified recombinant blood factor X developed for the treatment of severe spontaneous bleeding and for the prevention of bleeding during urgent surgery in patients taking oral factor Xa inhibitors (FXa DOACs) as anticoagulation therapy. The company is supported by a strong syndicate of investors. Jan K. Öhrström has been the CEO of the company since 2018. | - |
| Alex Gold | M | - |
Varmx BV
Varmx BV BiotechnologyHealth Technology VarmX BV is a spin-off from Leiden University Medical Center (LUMC) founded in 2016 by Professor Pieter Reitsma, a world-leading expert in hemostasis and thrombosis. VarmX is based in Leiden, NL. The Dutch company's lead compound, VMX-C001, is a modified recombinant blood factor X developed for the treatment of severe spontaneous bleeding and for the prevention of bleeding during urgent surgery in patients taking oral factor Xa inhibitors (FXa DOACs) as anticoagulation therapy. The company is supported by a strong syndicate of investors. Jan K. Öhrström has been the CEO of the company since 2018. | - |
| Kristina Dziekan | F | - | 2 Jahre | |
| Erika Ross | M | - | 1 Jahre | |
| Mary Ellen Hughes | F | - |
Blaze Bioscience, Inc.
Blaze Bioscience, Inc. Medical/Nursing ServicesHealth Services Blaze Bioscience, Inc. develops tumor paint products and Optide-based guided therapeutics for cancer patients. The firm provides BLZ-100. The company was founded by James M. Olson in 2010 and is headquartered in Seattle, WA. | - |
| Abbas Ardehali | M | - | 6 Jahre | |
| Sarah Moore | F | - | 1 Jahre | |
| Jan Disbergen | M | - |
Polyganics BV
 Polyganics BV Medical SpecialtiesHealth Technology Polyganics BV engages in the development, manufacture, and commercialization of bioresorbable medical devices that facilitate tissue repair and regeneration. It offers pipeline, peripheral nerve repair, neurosurgery, and general surgery products . The company was founded in 1999 and is headquartered in Groningen, the Netherlands. | 11 Jahre |
| Claudia Jochheim | M | - |
Blaze Bioscience, Inc.
Blaze Bioscience, Inc. Medical/Nursing ServicesHealth Services Blaze Bioscience, Inc. develops tumor paint products and Optide-based guided therapeutics for cancer patients. The firm provides BLZ-100. The company was founded by James M. Olson in 2010 and is headquartered in Seattle, WA. | - |
| Jeffrey Lawson | M | 60 |
Varmx BV
Varmx BV BiotechnologyHealth Technology VarmX BV is a spin-off from Leiden University Medical Center (LUMC) founded in 2016 by Professor Pieter Reitsma, a world-leading expert in hemostasis and thrombosis. VarmX is based in Leiden, NL. The Dutch company's lead compound, VMX-C001, is a modified recombinant blood factor X developed for the treatment of severe spontaneous bleeding and for the prevention of bleeding during urgent surgery in patients taking oral factor Xa inhibitors (FXa DOACs) as anticoagulation therapy. The company is supported by a strong syndicate of investors. Jan K. Öhrström has been the CEO of the company since 2018. | 1 Jahre |
| Ferrand Patrice | M | - | 5 Jahre | |
| Patrick van Beneden | M | 62 |
Onward Medical SA
Onward Medical SA BiotechnologyHealth Technology ONWARD Inc develops medical devices. It also provides stimulation system to rehabilitate individuals with spinal cord injury. The company was founded by Jocelyn Bloch, Sjaak Deckers, Grégoire Courtine, and Vincent Delattre in December 2014 and is headquartered in Lausanne, Switzerland. | - |
| Annemieke J. Wouterse | F | - |
Polyganics BV
Polyganics BV Medical SpecialtiesHealth Technology Polyganics BV engages in the development, manufacture, and commercialization of bioresorbable medical devices that facilitate tissue repair and regeneration. It offers pipeline, peripheral nerve repair, neurosurgery, and general surgery products . The company was founded in 1999 and is headquartered in Groningen, the Netherlands. | 12 Jahre |
| Erin Elizabeth Gainer | M | 50 | 6 Jahre | |
| Casper Breum | M | 57 |
Varmx BV
Varmx BV BiotechnologyHealth Technology VarmX BV is a spin-off from Leiden University Medical Center (LUMC) founded in 2016 by Professor Pieter Reitsma, a world-leading expert in hemostasis and thrombosis. VarmX is based in Leiden, NL. The Dutch company's lead compound, VMX-C001, is a modified recombinant blood factor X developed for the treatment of severe spontaneous bleeding and for the prevention of bleeding during urgent surgery in patients taking oral factor Xa inhibitors (FXa DOACs) as anticoagulation therapy. The company is supported by a strong syndicate of investors. Jan K. Öhrström has been the CEO of the company since 2018. | 4 Jahre |
| Romke S. R. Ribbels | M | - |
Polyganics BV
Polyganics BV Medical SpecialtiesHealth Technology Polyganics BV engages in the development, manufacture, and commercialization of bioresorbable medical devices that facilitate tissue repair and regeneration. It offers pipeline, peripheral nerve repair, neurosurgery, and general surgery products . The company was founded in 1999 and is headquartered in Groningen, the Netherlands. | 15 Jahre |
| Ralph Voncken | M | 53 |
Polyganics BV
Polyganics BV Medical SpecialtiesHealth Technology Polyganics BV engages in the development, manufacture, and commercialization of bioresorbable medical devices that facilitate tissue repair and regeneration. It offers pipeline, peripheral nerve repair, neurosurgery, and general surgery products . The company was founded in 1999 and is headquartered in Groningen, the Netherlands. | - |
| Camilla Sylvest | F | 52 | 28 Jahre | |
| Khaled Bahi | M | - | 1 Jahre | |
| Maziar Mike Doustdar | M | 54 | 32 Jahre | |
| Julia Novak | M | - |
Blaze Bioscience, Inc.
Blaze Bioscience, Inc. Medical/Nursing ServicesHealth Services Blaze Bioscience, Inc. develops tumor paint products and Optide-based guided therapeutics for cancer patients. The firm provides BLZ-100. The company was founded by James M. Olson in 2010 and is headquartered in Seattle, WA. | - |
| Simone Botti | M | - |
Varmx BV
Varmx BV BiotechnologyHealth Technology VarmX BV is a spin-off from Leiden University Medical Center (LUMC) founded in 2016 by Professor Pieter Reitsma, a world-leading expert in hemostasis and thrombosis. VarmX is based in Leiden, NL. The Dutch company's lead compound, VMX-C001, is a modified recombinant blood factor X developed for the treatment of severe spontaneous bleeding and for the prevention of bleeding during urgent surgery in patients taking oral factor Xa inhibitors (FXa DOACs) as anticoagulation therapy. The company is supported by a strong syndicate of investors. Jan K. Öhrström has been the CEO of the company since 2018. | - |
| Oskar Slotboom | M | - |
Varmx BV
Varmx BV BiotechnologyHealth Technology VarmX BV is a spin-off from Leiden University Medical Center (LUMC) founded in 2016 by Professor Pieter Reitsma, a world-leading expert in hemostasis and thrombosis. VarmX is based in Leiden, NL. The Dutch company's lead compound, VMX-C001, is a modified recombinant blood factor X developed for the treatment of severe spontaneous bleeding and for the prevention of bleeding during urgent surgery in patients taking oral factor Xa inhibitors (FXa DOACs) as anticoagulation therapy. The company is supported by a strong syndicate of investors. Jan K. Öhrström has been the CEO of the company since 2018. | - |
| Lars Gredsted | M | - |
Varmx BV
Varmx BV BiotechnologyHealth Technology VarmX BV is a spin-off from Leiden University Medical Center (LUMC) founded in 2016 by Professor Pieter Reitsma, a world-leading expert in hemostasis and thrombosis. VarmX is based in Leiden, NL. The Dutch company's lead compound, VMX-C001, is a modified recombinant blood factor X developed for the treatment of severe spontaneous bleeding and for the prevention of bleeding during urgent surgery in patients taking oral factor Xa inhibitors (FXa DOACs) as anticoagulation therapy. The company is supported by a strong syndicate of investors. Jan K. Öhrström has been the CEO of the company since 2018. | - |
| William D. Spotnitz | M | - | 9 Jahre | |
| Marie-Claire Fritsch | F | - | 6 Jahre |
Beziehungs-Chart
Beziehungen zu mehreren Unternehmen
Ehemalige Beziehungen
| Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
|---|---|---|---|---|
| Douglas Williams | M | 66 |
ZymoGenetics, Inc.
ZymoGenetics, Inc. Pharmaceuticals: MajorHealth Technology ZymoGenetics, Inc. develops protein based drugs. It focuses on the discovery, development, manufacture, and commercialization of therapeutic proteins for the treatment of human diseases, including homeostasis, inflammatory and autoimmune diseases, cancer, and viral infections. The company was founded by Earl W. Davie, Benjamin D. Hall and Michael Smith in 1981 and is headquartered in Seattle, WA. | 6 Jahre |
| Etienne Binant | M | - | - | |
| Jakob Riis | M | 58 | 21 Jahre | |
| Suzanne M. Shema | F | 66 |
ZymoGenetics, Inc.
ZymoGenetics, Inc. Pharmaceuticals: MajorHealth Technology ZymoGenetics, Inc. develops protein based drugs. It focuses on the discovery, development, manufacture, and commercialization of therapeutic proteins for the treatment of human diseases, including homeostasis, inflammatory and autoimmune diseases, cancer, and viral infections. The company was founded by Earl W. Davie, Benjamin D. Hall and Michael Smith in 1981 and is headquartered in Seattle, WA. | 11 Jahre |
| Mads Krogsgaard Thomsen | M | 63 |
University of Copenhagen
| 38 Jahre |
| Thomas Dyrberg | M | 69 |
University of Copenhagen
| 18 Jahre |
| James Johnson | M | 67 |
ZymoGenetics, Inc.
ZymoGenetics, Inc. Pharmaceuticals: MajorHealth Technology ZymoGenetics, Inc. develops protein based drugs. It focuses on the discovery, development, manufacture, and commercialization of therapeutic proteins for the treatment of human diseases, including homeostasis, inflammatory and autoimmune diseases, cancer, and viral infections. The company was founded by Earl W. Davie, Benjamin D. Hall and Michael Smith in 1981 and is headquartered in Seattle, WA. | 9 Jahre |
| Jean-Yves Quentel | M | 54 | - | |
| Carsten Hellmann | M | 60 | - | |
| Martin Jensen | M | 64 |
University of Copenhagen
| 10 Jahre |
| Caroline Lang | F | - | - | |
| Steen Meier Rønborg | M | 70 |
University of Copenhagen
| 3 Jahre |
| Jesper Brandgaard | M | 60 | 20 Jahre | |
| Pieter H. Reitsma | M | - |
Varmx BV
Varmx BV BiotechnologyHealth Technology VarmX BV is a spin-off from Leiden University Medical Center (LUMC) founded in 2016 by Professor Pieter Reitsma, a world-leading expert in hemostasis and thrombosis. VarmX is based in Leiden, NL. The Dutch company's lead compound, VMX-C001, is a modified recombinant blood factor X developed for the treatment of severe spontaneous bleeding and for the prevention of bleeding during urgent surgery in patients taking oral factor Xa inhibitors (FXa DOACs) as anticoagulation therapy. The company is supported by a strong syndicate of investors. Jan K. Öhrström has been the CEO of the company since 2018. | - |
| Carine Cochereau | F | - | 1 Jahre | |
| Harry Penner | M | 78 | 8 Jahre | |
| Marie-Claire Janailhac-Fritsch | F | 68 | - | |
| Karin Garre | M | 67 |
University of Copenhagen
| 3 Jahre |
| Bente Juel Riis | M | - |
University of Copenhagen
| 4 Jahre |
| Jørgen Nergaard Gøl | M | - |
University of Copenhagen
| 4 Jahre |
| Karsten Witt | M | 68 |
University of Copenhagen
| 3 Jahre |
| Jan Mikkelsen | M | 65 | 11 Jahre | |
| Annette Stube | F | 57 | 11 Jahre | |
| Janne Thyø Thomsen | F | 67 |
University of Copenhagen
| 3 Jahre |
| Liselotte Hyveled | F | 58 | 26 Jahre | |
| Peder Andersen | M | 72 |
University of Copenhagen
| 3 Jahre |
| Lisa Herold Ferbing | F | 65 |
University of Copenhagen
| 3 Jahre |
| Gitte L. Pedersen | F | 61 | 10 Jahre | |
| Zaiton binti Jamaluddin | F | 65 | 8 Jahre | |
| Lars Jannik Boberg-Ans | M | 68 |
University of Copenhagen
| 1 Jahre |
| Lars-Erik Brenøe | M | 63 |
University of Copenhagen
| 3 Jahre |
| Lillan Rejkjaer | M | - |
University of Copenhagen
| 3 Jahre |
| Peter Jens Lindholm Kurtzhals | M | - | 28 Jahre | |
| Thomas Dywremose | M | - |
University of Copenhagen
| 4 Jahre |
| Peter David Suzdak | M | 65 | 7 Jahre | |
| Lars Rebien Sørensen | M | 69 |
University of Copenhagen
| 1 Jahre |
| Lone Fønss Schrøder | F | 64 |
University of Copenhagen
| 3 Jahre |
| Niels Crone | M | - |
University of Copenhagen
| 1 Jahre |
| Kirsten Drejer | M | 68 | 9 Jahre | |
| Henrik Lawaetz | M | 69 |
University of Copenhagen
| 3 Jahre |
| Andreas Hasle | M | 69 |
University of Copenhagen
| 4 Jahre |
| Bjørn Høi Jensen | M | 62 |
University of Copenhagen
| 1 Jahre |
| Brian R. Burr | M | - |
University of Copenhagen
| 4 Jahre |
| Lars Green | M | 57 | 27 Jahre | |
| Stig Strøbæk | M | 60 | 30 Jahre | |
| Karsten Kielland | M | - |
University of Copenhagen
| 4 Jahre |
| Louis Illum Honoré | M | 62 |
University of Copenhagen
| 4 Jahre |
| Susanne L. Biltoft | F | 61 |
University of Copenhagen
| 8 Jahre |
| Christian Sagild | M | 64 |
University of Copenhagen
| 1 Jahre |
| Birgit Kjældgaard Giwercman | M | - |
University of Copenhagen
| 3 Jahre |
| Haibin Zheng | M | - |
University of Copenhagen
| 3 Jahre |
| Susanne Høiberg | M | - |
University of Copenhagen
| 4 Jahre |
| Susanne Hayes | F | - | 10 Jahre |
Statistik
| Land | Beziehungen | % des Gesamten |
|---|---|---|
| Dänemark | 50 | 50,00% |
| Niederlande | 27 | 27,00% |
| Frankreich | 12 | 12,00% |
| Vereinigte Staaten | 10 | 10,00% |
| Schweiz | 10 | 10,00% |
Alter der Beziehungen
Aktive
Vergangene
Herr
Frau
Aufsichtsräte
Führungskräfte
Ursprung der Beziehungen
- Börse
- Insiders
- Jan Öhrström
- Persönliches Netzwerk
